Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT-202
- Development stage
- Preclinical
- Lead developer
- HepaThera
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HT-202 is an investigational bispecific monoclonal antibody being developed by HepaThera Biotech for the treatment of chronic Hepatitis B Virus (HBV) infection. Designed as a T-cell engager, HT-202 simultaneously targets the Hepatitis B surface antigen (HBsAg) on infected hepatocytes and the CD3 receptor on T cells. This dual binding mechanism is intended to redirect T-cell-mediated cytotoxicity specifically toward HBV-infected cells, facilitating their clearance and potentially contributing to a functional cure for the disease. As of early 2024, the drug is in the preclinical stage of development, representing a novel immunotherapy approach within HepaThera's pipeline of biologics for chronic hepatitis B.
02
Targets
CD3 (T-cell surface glycoprotein CD3)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HT-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HT-202.